Enemem, In the 3-29-10 conf call, Varney said of the delay -- "What we have to do is, we have to generate the dosage forms (of CX-1739) and undertake some stability/release studies on those, and then submit that info along with other info in the IND."
Then at the 5-19-10 Shareholder's Meeting, the timeline given for starting the ADHD trial was Q3 (June, July, August).
So if they're planning to start the ADHD trial no later than August, the IND would presumably have to be filed at least a month or two (?) prior to that. Neuro may have a better estimate on the timeline. If filing the IND is considered a material event, perhaps we'll get a press release.
Market Data 
Markets 
AI
